---
document_datetime: 2023-09-21 18:07:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/neorecormon-epar-procedural-steps-taken-authorisation_en.pdf
document_name: neorecormon-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.370046
conversion_datetime: 2025-12-24 18:36:35.353793
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  company  Boehringer  Mannheim  GmbH.  submitted  on  10  October  1995  an  application  for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for NeoRecormon, in accordance with the centralised procedure falling within the scope of Part A of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 1 November 1995.
- The Rapporteur's initial assessment report was circulated to all  CPMP  Members  on 15  February  1996.  The  Co-Rapporteur's  assessment  report  was  circulated  to  all  CPMP Members on 15 February 1996.
- The CPMP consolidated list of questions was sent to the company on 15 March 1996 and the clock was stopped.
- The  company  submitted  the  responses  to  the  CPMP  consolidated  list  of  questions  on 1 August 1996 and the clock was restarted.
- The  Rapporteur's  and  Co-Rapporteur's  assessment  reports  to  the  company's  responses  was circulated to all CPMP members on 15 September 1996.
- A hearing with the company took place on 15 October 1996, to address the final outstanding issues.
- Amendments were made accordingly to the Summary of Product Characteristics and Package Leaflet texts.
- In the light of the overall data submitted and the scientific discussion within the Committee, the CPMP issued  a  positive  opinion  for  granting  a  marketing  authorisation  for  the  14  different presentations of NeoRecormon on 16 October 1996.
- The  CPMP  Opinions  were  forwarded  in  all  official  languages  of  the  EU  to  the  European Commission, which adopted the corresponding Decisions on 16 July 1997.

A.G. Hildebrandt

Co-Rapporteur: J.H. Trouvin